You are here: Industry Insights > NVX-CoV2373

News List

Novavax Announces positive preclinical data for combination influenza and COVID-19 vaccine candidate worldpharmanews
May 11, 2021
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced data from a preclinical study of the company's combination quadrivalent seasonal flu vaccine (NanoFlu™) and COVID-19 vaccine candidate.
Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility prnasia
May 07, 2021
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced that it has finalized an advance purchase agreement (APA) with Gavi, the Vaccine Alliance (Gavi) for supply of its recombinant ...
Novavax Covid-19 vaccine provides cross-protection against B.1.351 variant pharmaceutical-technology
May 07, 2021
The protein-based vaccine candidate NVX-CoV2373 is made from the genetic sequence of the first SARS-CoV-2 strain. It is adjuvanted with the company’s saponin-based Matrix-M to boost immune response and neutralising antibodies.
Novavax commences crossover arms in Covid-19 vaccine trials pharmaceutical-technology
April 06, 2021
Novavax has announced the start of crossover arms in the ongoing phase IIb South African trial and pivotal phase III UK trial of its Covid-19 vaccine candidate NVX-CoV2373.
GSK agrees to support manufacture of Novavax' COVID-19 vaccine pharmatimes
March 30, 2021
GlaxoSmithKline (GSK) has agreed in principle to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate – NVX-CoV2373 – for use in the UK.
Jubilant, Novavax Enter COVID-19 Vaccine Partnership contractpharma
March 30, 2021
Jubilant to provide fill-finish manufacturing services for the production of COVID-19 vaccine candidate NVX-CoV2373.
Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials prnasia
March 12, 2021
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced final efficacy of 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain in a pivotal Phase 3 ...
Novavax’s vaccine shows greater efficacy against Covid-19 variants pharmaceutical-technology
March 12, 2021
Novavax has reported that data from a pivotal Phase III trial of its vaccine candidate, NVX–CoV2373, in the UK showed an efficacy of 96.4% against mild, moderate and severe disease caused by the original Covid-19 strain.
Baxter Biopharma Solutions Enters Sterile Manufacturing Agreement for Novavax’ COVID-19 Vaccine contractpharma
March 10, 2021
New highly scalable line of bioreactors designed to ensure seamless scalability from early process development to commercial manufacturing.
Novavax concludes subject enrolment in Covid-19 vaccine trial pharmaceutical-technology
February 23, 2021
Biotechnology company Novavax has concluded enrolment in its pivotal Phase III PREVENT-19 study of Covid-19 vaccine candidate, NVX-CoV2373, in the US and Mexico.

Previous page 1 2 3 4 5 6 7 Next page